PBPIA
ALGS icon

Pivotal bioVenture Partners Investment Advisor’s Aligos Therapeutics ALGS Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,729
Closed -$260K – 12
2024
Q2 		$260K Hold
29,729
– – 0.2% 10
2024
Q1 		$728K Hold
29,729
– – 0.47% 11
2023
Q4 		$493K Hold
29,729
– – 0.13% 13
2023
Q3 		$555K Hold
29,729
– – 0.22% 13
2023
Q2 		$722K Hold
29,729
– – 0.24% 11
2023
Q1 		$650K Hold
29,729
– – 0.27% 11
2022
Q4 		$708K Hold
29,729
– – 0.31% 10
2022
Q3 		$818K Hold
29,729
– – 0.3% 11
2022
Q2 		$899K Sell
29,729
-5,333
-15% -$181K 0.45% 11
2022
Q1 		$1.89M Hold
35,062
– – 0.89% 11
2021
Q4 		$10.4M Hold
35,062
– – 4.35% 8
2021
Q3 		$13.6M Hold
35,062
– – 4.8% 7
2021
Q2 		$17.9M Hold
35,062
– – 7.04% 6
2021
Q1 		$19.9M Hold
35,062
– – 6.4% 6
2020
Q4 		$24.2M Buy
+35,062
New +$17.1M 7.99% 5

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's ALGS Position: Q3 2024 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 29,729 shares — an estimated $260K sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in ALGS in Q4 2020 and held it in 15 quarters. The position peaked at $24.2M in Q4 2020. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 29,729 Aligos Therapeutics shares in Q3 2024, an estimated $260K.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Aligos Therapeutics in Q4 2020 and held it in 15 quarters.
  • Pivotal bioVenture Partners Investment Advisor's Aligos Therapeutics position peaked at $24.2M in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2024, filed 13 Nov 2024.